Newamsterdam Pharma Company
36/100
Smart-money confidence
Below average interest
No standout activity across the feeds we track.
Stocks scoring 25–45 beat the S&P 500 45.3% of the time over the next three months, since 2015. How we measured this →
9
hedge funds
hold it · 3 new, 3 added, 1 trimmed
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Who's behind the signal
Every informed buyer we can see on NEWAMSTERDAM PHARMA COMPANY, across all three feeds.
Hedge funds · 9
Tudor Investment (Paul Tudor Jones)
New position
Point72 (Steve Cohen)
New position
D.E. Shaw & Co
New position
Maverick Capital (Ainslie)
Increased +50%
Millennium Management (Englander)
Increased +65%
AQR Capital Management
Increased +118%
+3 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
NEWAMSTERDAM PHARMA COMPANY isn't in the top-10 model right now, but 9 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
9
Investors
3
New positions
3
Increasing
1
Decreasing
2
Unchanged
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.2×
% of portfolio
0.0%
Position change
NEW
0.0% of Tudor Investment's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
NEW
0.0% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.2×
% of portfolio
1.0%
Position change
+50%
1.0% of Maverick Capital's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+65%
0.0% of Millennium Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+118%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.6×
% of portfolio
2.4%
Position change
—
2.4% of Duquesne Family Office's portfolio
Trust weight: 1.5×
% of portfolio
0.4%
Position change
—
0.4% of Viking Global Investors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−9%
0.0% of Citadel Advisors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to NEWAMSTERDAM PHARMA COMPANY
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell NEWAMSTERDAM PHARMA COMPANY or any security.